By Chris Wack
Shares of BioXcel Therapeutics rose after the company said it has reached 33% enrollment in a trial of a treatment for agitation associated with bipolar disorders or schizophrenia.
The biopharmaceutical company's stock was up 13%, to $3.10, midday Friday. The shares hit its 52-week low of $1.72 on Feb. 27, and are down 94% in the past 12 months.
BioXcel said the Phase 3 trial is designed to evaluate the safety of BXCL501. The trial's topline-data results, which are expected in the second half of 2025, are intended to support a potential supplemental new drug application submission to expand the label of the Food and Drug Administration-approved Igalmi sublingual film.
The New Haven, Conn., company's at-home trial currently has 67 patients enrolled, with 23 clinical trial sites open.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 07, 2025 14:09 ET (19:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。